Literature DB >> 17052231

Pro-survival signalling from the NMDA receptor.

G E Hardingham1.   

Abstract

Ca2+ influx through the NMDA (N-methyl-D-aspartate) subtype of ionotropic glutamate receptors plays a Jekyll and Hyde role in the mammalian central nervous system. While it mediates excitotoxic death triggered by stroke and other acute trauma, there is growing evidence that physiological levels of NMDA receptor activity promote survival. Understanding the mechanisms that underlie these opposing effects may lead to strategies to selectively block pro-death signalling, which could have considerable clinical benefits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052231      PMCID: PMC2837915          DOI: 10.1042/BST0340936

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  15 in total

Review 1.  Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway.

Authors:  A Brunet; S R Datta; M E Greenberg
Journal:  Curr Opin Neurobiol       Date:  2001-06       Impact factor: 6.627

Review 2.  The Yin and Yang of NMDA receptor signalling.

Authors:  Giles E Hardingham; Hilmar Bading
Journal:  Trends Neurosci       Date:  2003-02       Impact factor: 13.837

3.  Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability.

Authors:  Francesc X Soriano; Sofia Papadia; Frank Hofmann; Neil R Hardingham; Hilmar Bading; Giles E Hardingham
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

4.  Glutamate-induced neuron death requires mitochondrial calcium uptake.

Authors:  A K Stout; H M Raphael; B I Kanterewicz; E Klann; I J Reynolds
Journal:  Nat Neurosci       Date:  1998-09       Impact factor: 24.884

5.  Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection.

Authors:  Sofia Papadia; Patrick Stevenson; Neil R Hardingham; Hilmar Bading; Giles E Hardingham
Journal:  J Neurosci       Date:  2005-04-27       Impact factor: 6.167

Review 6.  Role of nitric oxide and calpain activation in neuronal death and survival.

Authors:  Inês M Araújo; Caetana M Carvalho
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2005-08

Review 7.  Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?

Authors:  Chrysanthy Ikonomidou; Lechoslaw Turski
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

Review 8.  Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury.

Authors:  M Arundine; M Tymianski
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

9.  Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons.

Authors:  Anton Ivanov; Christophe Pellegrino; Sylvain Rama; Iryna Dumalska; Yuriy Salyha; Yehezkel Ben-Ari; Igor Medina
Journal:  J Physiol       Date:  2006-05-01       Impact factor: 5.182

10.  Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity.

Authors:  Daniele Bano; Kenneth W Young; Christopher J Guerin; Ros Lefeuvre; Nancy J Rothwell; Luigi Naldini; Rosario Rizzuto; Ernesto Carafoli; Pierluigi Nicotera
Journal:  Cell       Date:  2005-01-28       Impact factor: 41.582

View more
  41 in total

1.  N-methyl-D-aspartate preconditioning prevents quinolinic acid-induced deregulation of glutamate and calcium homeostasis in mice hippocampus.

Authors:  S Vandresen-Filho; P C Severino; L C Constantino; W C Martins; S Molz; T Dal-Cim; D B Bertoldo; F R M B Silva; C I Tasca
Journal:  Neurotox Res       Date:  2014-11-04       Impact factor: 3.911

2.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

3.  Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage.

Authors:  A Vashishta; M Hetman
Journal:  Neuromolecular Med       Date:  2014-07-26       Impact factor: 3.843

Review 4.  Cause or compensation?-Altered neuronal Ca2+ handling in Huntington's disease.

Authors:  James P Mackay; Wissam B Nassrallah; Lynn A Raymond
Journal:  CNS Neurosci Ther       Date:  2018-02-09       Impact factor: 5.243

Review 5.  Role of Glutamate and NMDA Receptors in Alzheimer's Disease.

Authors:  Rui Wang; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

7.  Nuclear factor of activated T-cells isoform c4 (NFATc4/NFAT3) as a mediator of antiapoptotic transcription in NMDA receptor-stimulated cortical neurons.

Authors:  Aruna Vashishta; Agata Habas; Priit Pruunsild; Jing-Juan Zheng; Tõnis Timmusk; Michal Hetman
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

8.  Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.

Authors:  M Banasr; G M I Chowdhury; R Terwilliger; S S Newton; R S Duman; K L Behar; G Sanacora
Journal:  Mol Psychiatry       Date:  2008-09-30       Impact factor: 15.992

Review 9.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene.

Authors:  Bashayer Al-Mubarak; Francesc X Soriano; Giles E Hardingham
Journal:  Channels (Austin)       Date:  2009-07-24       Impact factor: 2.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.